Wednesday, 13 Dec 2017

You are here

Benlysta FDA Approved for Sub-Q Use in Lupus

The US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for use in active, autoantibody‑positive Systemic Lupus Erythematosus (SLE) patients. While the intravenous formulation was first approved in 2011, this becomes the first subcutaneous injectable treatment option SLE.

Patient may now receive a once weekly injection of 200mg, from either a single-dose prefilled syringe or from a single-dose autoinjector.

The approval is based on data from the BLISS-SC phase III pivotal study of more than 800 patients with active SLE, which measured reduction in disease activity at Week 52 in patients receiving belimumab plus standard of care, versus those receiving placebo plus standard of care (assessed by SRI, a composite measure of efficacy in lupus).

Benlysta subcutaneous formulation will be available in specialty pharmacies in the US in late August.

Benlystas worldwide sales were $398 million in 2016, with over 90% of sale from the USA.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Skin Remission in Dermatomyositis is Uncommon

JAMA Dermatology reports that clinical remission was relatively uncommon in dermatomyositis, despite aggressive systemic therapy, but was best in those receiving mycophenolate during a 3-year study.

Pregnancy Outcomes Worse with Myopathies

Women with the autoimmune inflammatory myopathies dermatomyositis (DM) and polymyositis (PM) are at increased risk for hypertensive disorders in pregnancy, a nationwide retrospective study found.

Health Economics of SLE

A number of presentations over the past few days have addressed the health economics of SLE.

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease.

EULAR/ACR SLE Classification Criteria Update

Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.